Drug Shortage Report for ULTRA-TECHNEKOW V4
| Report ID | 240205 |
| Drug Identification Number | 02441608 |
| Brand name | ULTRA-TECHNEKOW V4 |
| Common or Proper name | Sodium Pertechnetate Tc 99m Injection |
| Company Name | CURIUM CANADA INC |
| Market Status | MARKETED |
| Active Ingredient(s) | SODIUM PERTECHNETATE TC-99M |
| Strength(s) | 19CI |
| Dosage form(s) | SOLUTION |
| Route of administration | INTRAVENOUS INTRAVENOUS |
|
Packaging sizes (GTIN)
Click here to see a list of all reports for this drug. |
(See additional packaging sizes) |
| Additional packaging sizes | 1-19 curies |
| ATC code | V09FX |
| ATC description | |
| Reason for shortage | Shortage of an active ingredient. |
| Anticipated start date | 2024-10-21 |
| Actual start date | |
| Estimated end date | 2024-11-11 |
| Actual end date | 2024-11-11 |
| Shortage status | Resolved |
| Updated date | 2024-11-19 |
| Company comments | We have been informed by NRG, the operator of the HFR reactor, that a planned inspection of the reactor was recently completed, during which special attention was given to a previously identified deformation in one of the pipes, which is subject to a periodic monitoring program. The mitigation for this deformation was already planned to be executed during the upcoming December 2024 maintenance period. However, during the recent inspection it was determined that the repair must now be completed prior to the start of the next HFR cycle, which was planned for October 10. The current best estimate is that it will take at least a few weeks to finalize. Meanwhile, multiple other reactors that irradiate targets for global Mo 99 production are scheduled to be down for routine and planned maintenance over the coming weeks, and it appears that any meaningful schedule changes will not be possible. Consequently, we expect a significant reduction in global Mo 99 supply over the next several weeks, beginning with the week of October 20. Limited quantities of Mo 99 may be available during certain weeks, but detailed supply projections by day are not yet clear. We understand the significant impact this disruption in supply will have on normal business operations and patient scheduling. We are collaborating with other Mo 99 producers and partners across the industry in an effort to improve the situation and mitigate the impact on supply wherever possible. The situation is fluid, but we expect to be able to provide you with additional details in the coming days and weeks as we learn more. In the meantime, please don’t hesitate to contact a member of our Customer Service team or Sales team with any questions |
| Health Canada comments | |
| Tier 3 Status | No |
| Contact Address | 2572 BOUL. DANIEL-JOHNSON LAVAL, QUEBEC CANADA H7T 2R3 |
| Company contact information |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
| Version Number | Date Updated | Language | |
|---|---|---|---|
| v16 | 2024-11-19 | French | Compare |
| v15 | 2024-11-19 | English | Compare |
| v14 | 2024-11-07 | French | Compare |
| v13 | 2024-11-07 | English | Compare |
| v12 | 2024-10-22 | English | Compare |
| v11 | 2024-10-16 | English | Compare |
| v10 | 2024-10-16 | French | Compare |
| v9 | 2024-10-16 | French | Compare |
| v8 | 2024-10-16 | English | Compare |
| v7 | 2024-10-15 | French | Compare |
| v6 | 2024-10-15 | English | Compare |
| v5 | 2024-10-15 | French | Compare |
| v4 | 2024-10-15 | English | Compare |
| v3 | 2024-10-15 | English | Compare |
| v2 | 2024-10-15 | English | Compare |
| v1 | 2024-10-15 | English | Compare |
Showing 1 to 16 of 16